SciSparc (SPRC) Competitors $3.82 -0.11 (-2.80%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$3.78 -0.03 (-0.92%) As of 10/17/2025 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SPRC vs. TNFA, VIVS, KZIA, ALZN, PLRZ, PMCB, SNGX, SNOA, QLGN, and NLSPShould you be buying SciSparc stock or one of its competitors? The main competitors of SciSparc include TNF Pharmaceuticals (TNFA), VivoSim Labs (VIVS), Novogen (KZIA), Alzamend Neuro (ALZN), Polyrizon (PLRZ), Nuvilex (PMCB), Soligenix (SNGX), Sonoma Pharmaceuticals (SNOA), Qualigen Therapeutics (QLGN), and NLS Pharmaceutics (NLSP). These companies are all part of the "pharmaceutical products" industry. SciSparc vs. Its Competitors TNF Pharmaceuticals VivoSim Labs Novogen Alzamend Neuro Polyrizon Nuvilex Soligenix Sonoma Pharmaceuticals Qualigen Therapeutics NLS Pharmaceutics TNF Pharmaceuticals (NASDAQ:TNFA) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations. Do institutionals & insiders have more ownership in TNFA or SPRC? 9.6% of TNF Pharmaceuticals shares are held by institutional investors. Comparatively, 25.1% of SciSparc shares are held by institutional investors. 0.5% of TNF Pharmaceuticals shares are held by insiders. Comparatively, 1.5% of SciSparc shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is TNFA or SPRC more profitable? SciSparc's return on equity of 0.00% beat TNF Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets TNF PharmaceuticalsN/A -69.21% -33.98% SciSparc N/A N/A N/A Do analysts rate TNFA or SPRC? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TNF Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00SciSparc 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has better valuation and earnings, TNFA or SPRC? SciSparc has higher revenue and earnings than TNF Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTNF PharmaceuticalsN/AN/A-$23.36M-$231.00-0.02SciSparc$1.31M1.55-$6.28MN/AN/A Which has more volatility & risk, TNFA or SPRC? TNF Pharmaceuticals has a beta of 2.04, meaning that its share price is 104% more volatile than the S&P 500. Comparatively, SciSparc has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Does the media favor TNFA or SPRC? In the previous week, SciSparc had 7 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 7 mentions for SciSparc and 0 mentions for TNF Pharmaceuticals. SciSparc's average media sentiment score of 1.00 beat TNF Pharmaceuticals' score of 0.00 indicating that SciSparc is being referred to more favorably in the news media. Company Overall Sentiment TNF Pharmaceuticals Neutral SciSparc Positive SummarySciSparc beats TNF Pharmaceuticals on 8 of the 9 factors compared between the two stocks. Get SciSparc News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRC vs. The Competition Export to ExcelMetricSciSparcMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.04M$3.02B$6.20B$10.53BDividend YieldN/A54.20%5.70%4.82%P/E RatioN/A23.3185.7027.13Price / Sales1.55597.25580.78177.79Price / CashN/A169.4137.1060.81Price / Book0.215.3212.236.52Net Income-$6.28M$33.06M$3.33B$276.93M7 Day Performance-4.74%2.29%1.17%1.93%1 Month Performance-19.92%7.35%6.85%2.19%1 Year Performance-20.63%-5.13%58.93%34.62% SciSparc Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRCSciSparc0.5129 of 5 stars$3.82-2.8%N/A-20.6%$2.04M$1.31M0.004Positive NewsGap DownTNFATNF Pharmaceuticals0.0683 of 5 stars$3.89+5.7%N/A-97.5%$7.19MN/A-0.026VIVSVivoSim Labs1.2206 of 5 stars$2.74-7.4%N/AN/A$7.12M$140K-0.2720Short Interest ↓KZIANovogen3.8912 of 5 stars$6.98+2.5%$16.50+136.4%-72.1%$7.05M$1.51M0.0012Short Interest ↓Gap UpALZNAlzamend Neuro2.4527 of 5 stars$2.24+1.8%$42.00+1,775.0%-85.3%$7.03MN/A0.004News CoverageAnalyst ForecastShort Interest ↑PLRZPolyrizonN/A$1.17-0.8%N/AN/A$7.01MN/A0.00N/APositive NewsShort Interest ↓Gap DownPMCBNuvilex0.0854 of 5 stars$1.03+3.0%N/A-43.3%$7.00MN/A-1.914Short Interest ↑High Trading VolumeSNGXSoligenix2.4602 of 5 stars$1.63-5.2%$6.00+268.1%-57.4%$6.99M$120K-0.4320SNOASonoma Pharmaceuticals1.0875 of 5 stars$4.07flatN/A+21.2%$6.68M$14.29M-1.65180News CoverageQLGNQualigen TherapeuticsN/A$3.81-5.0%N/A-56.5%$6.48M$4.98M0.0050Short Interest ↑Gap DownNLSPNLS PharmaceuticsN/A$1.78+0.6%N/A-69.1%$6.41MN/A0.006News CoverageAnalyst ForecastShort Interest ↑Gap Down Related Companies and Tools Related Companies TNFA Alternatives VIVS Alternatives KZIA Alternatives ALZN Alternatives PLRZ Alternatives PMCB Alternatives SNGX Alternatives SNOA Alternatives QLGN Alternatives NLSP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRC) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SciSparc Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share SciSparc With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
